Bioenvision to Hold Fiscal 2006 Year-End Financial Results Conference Call Monday, September 11, 2006

Bioenvision, Inc. (NasdaqGM:BIVN) will release fiscal
2006 year-end financial results at 7 a.m. Eastern Daylight Time on
September 11, 2006.
   Christopher B. Wood, Chairman and CEO and David P. Luci, CFO and
General Counsel, will host an investment conference call beginning at:
12 p.m. Eastern Daylight Time on September 11, 2006 to discuss these
results and to answer questions.

   Conference Call Information:

   Date: 9/11/2006

   Time: 12:00PM Eastern

   Toll free: 866-585-6398

   International: 416-849-9626

   Web cast: www.bioenvision.com

   A replay of the call and web cast will be available for 14 days.

   Replay number: 866-245-6755

   Replay number international: 416-915-1035

   Replay passcode: 739924

   Web cast replay: www.bioenvision.com

   About Bioenvision

   Bioenvision's primary focus is the acquisition, development,
distribution and marketing of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products for
the treatment of cancer, including: Evoltra(R), Modrenal(R) (for which
Bioenvision has obtained regulatory approval for marketing in the
United Kingdom for the treatment of post-menopausal breast cancer
following relapse to initial hormone therapy), and other products.
Bioenvision is also developing anti-infective technologies, including
the OLIGON(R) technology; an advanced biomaterial that has been
incorporated into various FDA approved medical devices and Suvus(TM),
an antimicrobial agent currently in clinical development for
refractory chronic hepatitis C infection. For more information on
Bioenvision please visit our Web site at www.bioenvision.com.

   Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Specifically,
factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include,
but are not limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the potential
failure of Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure to
successfully implement or complete clinical trials; failure to receive
marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure or
projections; the development of competing products; uncertainties
related to Bioenvision's dependence on third parties and partners; and
those risks described in Bioenvision's filings with the SEC.
Bioenvision disclaims any obligation to update these forward-looking
statements.